UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended July 3, 2016
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
COMMISSION FILE NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State of Incorporation)
13-5315170
(I.R.S. Employer Identification No.)
235 East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant s telephone number)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
YES X
NO ___
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
YES X
NO ___
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act (check one):
Large Accelerated filer X Accelerated filer ___ Non-accelerated filer ___ Smaller reporting company ___
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YES ____
NO X
At August 8, 2016, 6,065,652,424 shares of the issuer s voting common stock were outstanding.
Table of Contents
PART I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements
Condensed Consolidated Statements of Income for the three and six months ended July 3, 2016 and June 28, 2015
Condensed Consolidated Statements of Comprehensive Income for the three and six months ended July 3, 2016 and June 28, 2015
Condensed Consolidated Balance Sheets as of July 3, 2016 and December 31, 2015
Condensed Consolidated Statements of Cash Flows for the six months ended July 3, 2016 and June 28, 2015
Notes to Condensed Consolidated Financial Statements
Review Report of Independent Registered Public Accounting Firm
47
Item 2.
Management s Discussion and Analysis of Financial Condition and Results of Operations
48
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
101
Item 4.
Controls and Procedures
101
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
102
Item 1A.
Risk Factors
102
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
103
Item 3.
Defaults Upon Senior Securities
103
Item 4.
Mine Safety Disclosures
103
Item 5.
Other Information
103
Item 6.
Exhibits
104
Signature
105
GLOSSARY OF DEFINED TERMS
Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Quarterly Report on Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined below:
2015 Financial Report
Financial Report for the fiscal year ended December 31, 2015, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2015
2015 Form 10-K
Annual Report on Form 10-K for the fiscal year ended December 31, 2015
ACA
U.S. Patient Protection and Affordable Care Act, as amended by the Health Care Reconciliation Act
ACIP
Advisory Committee on Immunization Practices
ALK
anaplastic lymphoma kinase
Allergan
Allergan plc
Alliance revenues
revenues from alliance agreements under which we co-promote products discovered by other companies
AM-Pharma
AM-Pharma B.V.
Anacor
Anacor Pharmaceuticals, Inc.
ASU
Accounting Standards Update
Baxter
Baxter International Inc.
BMS
Bristol-Myers Squibb Company
CDC
U.S. Centers for Disease Control and Prevention
Developed Markets
U.S., Western Europe, Japan, Canada, Australia, Scandinavia, South Korea, Finland and New Zealand
DOJ
U.S. Department of Justice
DVT
deep vein thrombosis
EEA
European Economic Area
EH
Essential Health
EMA
European Medicines Agency
Emerging Markets
Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey
EPA
U.S. Environmental Protection Agency
EPS
earnings per share
EU
European Union
Exchange Act
Securities Exchange Act of 1934, as amended
FASB
Financial Accounting Standards Board
FDA
U.S. Food and Drug Administration
GAAP
Generally Accepted Accounting Principles
GHD
growth hormone deficiency
GIST
gastrointestinal stromal tumors
GEP
Global Established Pharmaceutical segment
GIP
Global Innovative Pharmaceutical segment
GPD
Global Product Development organization
GS&Co.
Goldman, Sachs & Co.
HER2-
human epidermal growth factor receptor 2-negative
hGH-CTP
human growth hormone
Hisun Pfizer
Hisun Pfizer Pharmaceuticals Company Limited
Hospira
Hospira, Inc.
HR+
hormone receptor-positive
IH
Innovative Health
IPR&D
in-process research and development
IRC
Internal Revenue Code
IRS
U.S. Internal Revenue Service
LDL
low density lipoprotein
Lilly
Eli Lilly & Company
LOE
loss of exclusivity
MCO
managed care organization
MD&A
Management s Discussion and Analysis of Financial Condition and Results of Operations
MDV
multi-dose vial
Moody s
Moody s Investors Service
mRCC
metastatic renal cell carcinoma
NDA
new drug application
NOAC
Novel Oral Anticoagulant
NovaQuest
NovaQuest Co-Investment Fund II, L.P. or NovaQuest Co-Investment Fund V, L.P., as applicable
NSCLC
non-small cell lung cancer
NYSE
New York Stock Exchange
OPKO
OPKO Health, Inc.
OTC
over-the-counter
PBM
Pharmacy Benefit Manager
PDUFA
Prescription Drug User Fee Act
PE
pulmonary embolism
PGS
Pfizer Global Supply
Pharmacia
Pharmacia Corporation
PP&E
Property, plant & equipment
Quarterly Report on Form 10-Q
Quarterly Report on Form 10-Q for the quarterly period ended July 3, 2016
RAR
Revenue Agent s Report
RCC
renal cell carcinoma
recAP
recombinant human Alkaline Phosphatase
R&D
research and development
RPI
RPI Finance Trust
Sandoz
Sandoz, Inc., a division of Novartis AG
SEC
U.S. Securities and Exchange Commission
SGA
small for gestational age
S&P
Standard and Poor s
Teuto
Laborat rio Teuto Brasileiro S.A.
U.K.
United Kingdom
U.S.
United States
VAT
value added tax
VOC
Global Vaccines, Oncology and Consumer Healthcare segment
WRD
Worldwide Research and Development
Zoetis
Zoetis Inc.
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three Months Ended
Six Months Ended
(MILLIONS, EXCEPT PER COMMON SHARE DATA)
July 3,
2016
June 28,
2015
July 3,
2016
June 28,
2015
Revenues
13,147
11,853
26,152
22,717
Costs and expenses:
Cost of sales(a)
3,174
2,180
6,026
4,018
Selling, informational and administrative expenses(a)
3,471
3,386
6,856
6,491
Research and development expenses(a)
1,748
1,734
3,478
3,620
Amortization of intangible assets
961
872
1,966
1,811
Restructuring charges and certain acquisition-related costs
316
86
457
146
Other (income)/deductions net
1,068
55
1,398
Income from continuing operations before provision for taxes on income
2,410
3,539
5,971
6,621
Provision for taxes on income
375
905
910
1,610
Income from continuing operations
2,035
2,635
5,060
5,011
Discontinued operations net of tax
Net income before allocation to noncontrolling interests
2,035
2,635
5,061
5,017
Less: Net income attributable to noncontrolling interests
16
25
14
Net income attributable to Pfizer Inc.
2,019
2,626
5,036
5,002
Earnings per common share basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.33
0.43
0.82
0.81
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
0.33
0.43
0.82
0.81
Earnings per common share diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.33
0.42
0.82
0.80
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
0.33
0.42
0.82
0.80
Weighted-average shares basic
6,068
6,159
6,110
6,181
Weighted-average shares diluted
6,137
6,243
6,176
6,267
Cash dividends paid per common share
0.30
0.28
0.60
0.56
(a)
Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill:Identifiable Intangible Assets.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
Three Months Ended
Six Months Ended
(MILLIONS OF DOLLARS)
July 3,
2016
June 28,
2015
July 3,
2016
June 28,
2015
Net income before allocation to noncontrolling interests
2,035
2,635
5,061
5,017
Foreign currency translation adjustments, net
514
(327
581
(1,635
514
(327
581
(1,635
Unrealized holding gains/(losses) on derivative financial instruments, net
(571
452
(845
137
Reclassification adjustments for realized (gains)/losses(a)
469
(743
130
(510
(102
(291
(714
(373
Unrealized holding gains/(losses) on available-for-sale securities, net
350
(200
479
(527
Reclassification adjustments for realized (gains)/losses(a)
(226
498
(16
745
124
299
463
218
Benefit plans: actuarial gains/(losses), net
(19
(9
(19
22
Reclassification adjustments related to amortization(b)
139
134
278
269
Reclassification adjustments related to settlements, net(b)
22
22
48
62
Other
(57
(29
(18
130
85
118
288
483
Benefit plans: prior service credits and other, net
87
507
87
506
Reclassification adjustments related to amortization(b)
(41
(34
(81
(69
Reclassification adjustments related to curtailments, net(b)
(7
(6
(17
Other
(2
(2
48
464
418
Other comprehensive income/(loss), before tax
669
263
624
(890
Tax provision/(benefit) on other comprehensive income/(loss)(c)
36
228
(5
332
Other comprehensive income/(loss) before allocation to noncontrolling interests
633
35
629
(1,222
Comprehensive income before allocation to noncontrolling interests
2,668
2,670
5,690
3,795
Less: Comprehensive income/(loss) attributable to noncontrolling interests
21
24
(3
Comprehensive income attributable to Pfizer Inc.
2,647
2,663
5,666
3,797
(a)
Reclassified into Other (income)/deductions net in the condensed consolidated statements of income.
(b)
Generally reclassified, as part of net periodic pension cost, into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, in the condensed consolidated statements of income. For additional information, see Note 10. Pension and Postretirement Benefit Plans.
(c)
See Note 5C. Tax Matters: Tax Provision/(Benefit) on Other Comprehensive Income/(Loss).
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(MILLIONS OF DOLLARS)
July 3,
2016
December 31,
2015
(Unaudited)
Assets
Cash and cash equivalents
3,411
3,641
Short-term investments
17,531
19,649
Trade accounts receivable, less allowance for doubtful accounts: 2016 $670; 2015 $384
9,138
8,176
Inventories
7,614
7,513
Current tax assets
3,127
2,662
Other current assets
3,023
2,163
Total current assets
43,845
43,804
Long-term investments
13,124
15,999
Property, plant and equipment, less accumulated depreciation: 2016 $14,637; 2015 $13,502
13,609
13,766
Identifiable intangible assets, less accumulated amortization
43,056
40,356
Goodwill
50,600
48,242
Noncurrent deferred tax assets and other noncurrent tax assets
1,805
1,794
Other noncurrent assets
4,618
3,420
Total assets
170,658
167,381
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt
13,724
10,159
Trade accounts payable
3,261
3,620
Dividends payable
1,820
1,852
Income taxes payable
647
418
Accrued compensation and related items
1,594
2,359
Other current liabilities
11,053
10,990
Total current liabilities
32,099
29,399
Long-term debt
30,457
28,740
Pension benefit obligations, net
5,224
6,310
Postretirement benefit obligations, net
1,877
1,809
Noncurrent deferred tax liabilities
28,300
26,877
Other taxes payable
4,116
3,992
Other noncurrent liabilities
5,518
5,257
Total liabilities
107,592
102,384
Commitments and Contingencies
Preferred stock
25
26
Common stock
461
459
Additional paid-in capital
82,138
81,016
Treasury stock
(84,313
(79,252
Retained earnings
73,350
71,993
Accumulated other comprehensive loss
(8,891
(9,522
Total Pfizer Inc. shareholders equity
62,769
64,720
Equity attributable to noncontrolling interests
297
278
Total equity
63,066
64,998
Total liabilities and equity
170,658
167,381
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Six Months Ended
(MILLIONS OF DOLLARS)
July 3,
2016
June 28,
2015
Operating Activities
Net income before allocation to noncontrolling interests
5,061
5,017
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization
2,812
2,461
Asset write-offs and impairments
983
42
Deferred taxes from continuing operations
(10
(183
Share-based compensation expense
387
347
Benefit plan contributions in excess of expense
(857
(842
Other adjustments, net
170
(194
Other changes in assets and liabilities, net of acquisitions and divestitures
(3,316
(1,879
Net cash provided by operating activities
5,230
4,770
Investing Activities
Purchases of property, plant and equipment
(702
(497
Purchases of short-term investments
(8,744
(16,029
Proceeds from redemptions/sales of short-term investments
14,757
20,483
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less
(249
3,020
Purchases of long-term investments
(3,126
(5,422
Proceeds from redemptions/sales of long-term investments
2,427
3,291
Acquisitions of businesses, net of cash acquired
(4,616
(679
Acquisitions of intangible assets
(96
(12
Other investing activities, net
26
333
Net cash (used in)/provided by investing activities
(323
4,487
Financing Activities
Proceeds from short-term borrowings
2,307
2,022
Principal payments on short-term borrowings
(2,291
(11
Net proceeds from short-term borrowings with original maturities of three months or less
2,182
481
Proceeds from issuance of long-term debt
5,031
Principal payments on long-term debt
(4,317
(2,995
Purchases of common stock
(5,000
(6,000
Cash dividends paid
(3,675
(3,483
Proceeds from exercise of stock options
696
981
Other financing activities, net
(2
154
Net cash used in financing activities
(5,069
(8,852
Effect of exchange-rate changes on cash and cash equivalents
(68
(78
Net increase/(decrease) in cash and cash equivalents
(230
327
Cash and cash equivalents, beginning
3,641
3,343
Cash and cash equivalents, end
3,411
3,670
Supplemental Cash Flow Information
Cash paid during the period for:
Income taxes
1,111
1,124
Interest
903
914
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of Presentation and Significant Accounting Policies
A. Basis of Presentation
See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes of this Quarterly Report on Form 10-Q.
We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted.
The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the three and six months ended May 29, 2016 and May 24, 2015. The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three and six months ended July 3, 2016 and June 28, 2015.
Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our condensed consolidated balance sheets and condensed consolidated statements of income. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2015 Form 10-K.
Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Quarterly Report on Form 10-Q refer to Pfizer Inc. and its subsidiaries.
Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.
Effective in the second quarter of 2016, our segments were reorganized to reflect that we now manage our innovative pharmaceutical and consumer healthcare operations as one business segment, Pfizer Innovative Health (IH) (previously these businesses were managed as two segments: the GIP segment and the VOC segment). Also, in the second quarter of 2016, we changed the name of our Established Products business to Pfizer Essential Health (EH). We have revised prior-period segment information to reflect the reorganization. For additional information, see Note 13.
In the condensed consolidated balance sheet as of December 31, 2015, we performed certain reclassifications to conform to the current period presentation of Other current assets, Other noncurrent assets, Short-term borrowings, including current portion of long-term debt and Long-term debt, and in the condensed consolidated statement of cash flows for the six months ended June 28, 2015, we performed certain reclassifications to conform to the current presentation of Proceeds from short-term borrowings for debt issuance costs in accordance with the adoption of a new accounting standard (for additional information, see Note 1B).
On June 24, 2016 (the acquisition date), we completed our acquisition of Anacor for $99.25 per share. The total fair value of consideration transferred for Anacor was approximately $4.9 billion in cash ($4.5 billion, net of cash acquired), plus $698 million debt assumed. Commencing from the acquisition date, our financial statements reflect the assets, liabilities and cash flows of Anacor. The operating results for Anacor for five days from June 24, 2016 to July 3, 2016 were immaterial. See Note 2A for additional information.
On April 6, 2016, we announced that the merger agreement between Pfizer and Allergan entered into on November 22, 2015 was terminated by mutual agreement of the companies. The decision was driven by the actions announced by the U.S. Department of Treasury on April 4, 2016, which the companies concluded qualified as an Adverse Tax Law Change under the merger agreement. In connection with the termination of the merger agreement, on April 8, 2016 (which falls into Pfizer s second fiscal quarter), Pfizer paid Allergan $150 million (pre-tax) for reimbursement of Allergan s expenses associated with the terminated transaction (see Note 4). Pfizer and Allergan also released each other from any and all claims in connection with the merger agreement.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
On September 3, 2015, we completed our acquisition of Hospira and, commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Hospira. As a result, legacy Hospira operations are reflected in our results of operations, EH s operating results, and cash flows for the second quarter and first six months of 2016, but not for the second quarter and first six months of 2015. Legacy Hospira assets and liabilities are reflected in our balance sheets as of July 3, 2016 and December 31, 2015.
B. Adoption of New Accounting Standards
We adopted a new standard as of January 1, 2016 that changed the presentation of debt issuance costs related to a recognized debt liability as a direct deduction from the carrying value of that associated debt, consistent with the presentation of a debt discount. The update does not impact the measurement or recognition of debt issuance costs. As of July 3, 2016, debt issuance costs were $93 million and are presented as contra-liabilities to Short-term borrowings, including current portion of long-term debt ($2 million) and Long-term debt ($91 million). In the December 31, 2015 condensed consolidated balance sheet, we have reclassified debt issuance costs of $79 million ($1 million from Other current assets and $79 million from Other noncurrent assets) and have presented them as contra-liabilities to Short-term borrowings, including current portion of long-term debt ($1 million) and Long-term debt ($79 million) to conform to the current period presentation. For additional information, see Note 7A.
We adopted a new standard as of January 1, 2016 that requires an acquirer to recognize adjustments made in the measurement period to provisional amounts of assets acquired and liabilities assumed in a business combination in the reporting period in which the adjustment amounts are determined. There was no material impact to our condensed consolidated financial statements in the second quarter and first six months of 2016 from adopting this standard. For additional information, see Note 2A.
We adopted a new standard as of January 1, 2016 related to the accounting for hybrid financial instruments issued or held as investments and there was no material impact to our condensed consolidated financial statements from adopting this standard.
C. Fair Value
Our fair value methodologies depend on the following types of inputs:
Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).
Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).
Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).
A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.
Note 2. Acquisitions, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment
A. Acquisitions
Anacor Pharmaceuticals, Inc.
On June 24, 2016 (the acquisition date), we completed our acquisition of Anacor for $99.25 per share. The total fair value of consideration transferred for Anacor was approximately $4.9 billion in cash ($4.5 billion net of cash acquired), plus $698 million debt assumed. Anacor is now a wholly-owned subsidiary of Pfizer. Anacor is a biopharmaceutical company focused on novel small-molecule therapeutics derived from its boron chemistry platform. Included within Anacor s pipeline is crisaborole, a non-steroidal topical PDE-4 inhibitor with anti-inflammatory properties. In connection with this acquisition, we recorded $698 million as the fair value of notes payable in cash, and provisionally recorded $5.0 billion in Identifiable intangible assets, primarily consisting of $4.8 billion of In-process research and development, and provisionally recorded $1.8 billion of Goodwill and $1.6 billion of net deferred tax liabilities. The allocation of the consideration transferred to the assets acquired and the liabilities assumed has not been finalized.
10
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Hospira, Inc.
On September 3, 2015 (the acquisition date), we acquired Hospira, a leading provider of sterile injectable drugs and infusion technologies as well as a provider of biosimilars, for $90 per share in cash. The total fair value of consideration transferred for Hospira was approximately $16.1 billion in cash ($15.7 billion, net of cash acquired). Hospira is now a subsidiary of Pfizer. The combination of local Pfizer and Hospira entities may be pending in various jurisdictions and integration is subject to completion of various local legal and regulatory steps.
The following table summarizes the provisional amounts recognized for assets acquired and liabilities assumed as of the acquisition date, as well as adjustments made in the first six months of 2016 to the provisional amounts initially recorded in 2015 (measurement period adjustments) with a corresponding change to goodwill. Certain estimated values are not yet finalized (see below) and are subject to change. We will finalize the amounts recognized as we obtain the information necessary to complete the analyses, but no later than one year from the acquisition date.